



FOR IMMEDIATE RELEASE

Edimer Pharmaceuticals Presents EDI200 Update to International Gathering of Ectodermal Dysplasia Patient Foundations

-- Multinational Patient Registry Launched to Aid Research and Future Clinical Trial Recruitment --

VIENNA, Austria – October 15, 2010 – Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced that Neil Kirby, Ph.D., President & Chief Executive Officer of Edimer, presented an update on the company's lead compound, EDI200, to the International Ectodermal Dysplasia Meeting in Vienna, a gathering of 14 ectodermal dysplasia patient foundations from around the world. This meeting serves as a forum for the discussion of scientific and medical information about ectodermal dysplasias. XLHED affects primarily boys and, in its most severe form, is associated with serious and potentially life-threatening illness in infancy resulting from a lack of sweating leading to hyperthermia and from respiratory infections. In addition, affected individuals commonly have clinically significant abnormalities of teeth, hair, and tear ducts. There are currently no FDA-approved treatments for XLHED.

EDI200 has demonstrated durable effectiveness with short-course therapy in two animal models of XLHED, with improvements noted in respiratory gland development associated with a marked reduction in infections, as well as improvements in tearing, permanent teeth formation and sweat gland formation. EDI200 is the first therapy ever developed to treat XLHED and clinical trials are planned to start in the second half of 2011. EDI200 was granted Orphan Drug designation by the United States Food and Drug Administration (FDA) and the *Committee for Orphan Medicinal Products (COMP)* of the European Medicines Agency (EMA).

Edimer is supporting the development and maintenance of the Ectodermal Dysplasias International Registry, launched by the National Foundation for Ectodermal Dysplasias. The registry is an international scientific endeavor designed to advance knowledge on all ectodermal dysplasias worldwide. Patients can access the Registry at <http://nfed.patientcrossroads.org/>.

“As is the case with many rare diseases, there is only limited data currently available on the natural history of this serious, potentially life-threatening disorder. However, by sharing scientific and medical knowledge among the patient advocacy community worldwide and supporting the ongoing rollout of the international patient registry, there is a great opportunity to make significant strides in developing safe and effective drugs for this unmet medical need,” said Neil Kirby, Ph.D. “Edimer looks forward to continuing our support of the registry and ongoing communication efforts among the XLHED community who are an invaluable resource as we move EDI200 towards human trials.”

Dr. Kirby's presentation provided a comprehensive update on the initial development of EDI200 including a review of the upcoming milestones that comprise the clinical development of EDI200. Dr. Kirby also reviewed the company's recently announced partnership with CMC Biologics to scale-up production of EDI200 and manufacture cGMP material for use in the upcoming clinical and preclinical studies.

"I am grateful for Edimer's contribution to make this meeting successful," said Ulrike Holzer, vice-chair of the German-speaking Associations and spokeswoman of the European Associations. "With Edimer's support, a number of smaller patient associations were able to attend this important meeting and learn about the patient registry and progress being made in the development of EDI200."

"The development of EDI200 has the potential to make a major difference in the lives of children born with XLHED and is a significant leap forward in our goal to find a treatment for the disorder," said Mary Kaye Richter, Parent and NFED Founder and Executive Director. "We are grateful for Edimer's scientific and medical commitment to XLHED and their ongoing financial support of the patient registry which will allow for the continuing characterization of the disorder."

About XLHED

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) is a rare genetic disorder diagnosed on the basis of fine, sparse hair (hypotrichosis); few and often pointed teeth (hypodontia); and diminished or absent sweat function (hypohidrosis). XLHED, the X-linked form of hypohidrotic ectodermal dysplasia is associated with mutations in the EDA gene and is the most common of over 170 different ectodermal dysplasias. There are a number of secondary features of XLHED that may include a reduction in mucous glands in the pharynx, larynx, trachea and bronchi, dry eye symptoms, eczema, asthma and dry mucous membranes in the mouth and nose. As an X-linked genetic disorder, males with their single X-chromosome are fully affected by XLHED, while females inheriting one normal and one altered X-chromosome are variably affected.

In the first years of life, XLHED-affected individuals are at risk for severe medical complications, most often associated with their inability to sweat, leading to hyperthermia, and their reduced mucous secretion predisposing them to respiratory infections. Through childhood, the focus of medical care for XLHED patients may shift to the chronic skin issues and severe hypodontia with its associated medical and self-esteem issues. The average adult tooth count in male patients affected with XLHED is only 6, and the few remaining teeth often are conical or peg-like. Dentures may be prescribed as early as age 2-3 years to enhance feeding, growth, and speech and to begin to address what are often life-long psychosocial issues.

About EDI200

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy individuals that is involved in the formation of sweat glands, teeth, hair and certain glandular structures. This protein is missing in patients with XLHED. EDI200 is an investigational protein therapeutic being developed by Edimer as a treatment for certain patients with XLHED. EDI200 has been shown to substitute for lack of functional EDA-A1 protein in preclinical models of XLHED.

About Edimer Pharmaceuticals

Edimer is a privately held biotechnology company based in Cambridge, Massachusetts dedicated to delivering a significant and durable improvement in the health and quality of life to future generations affected by XLHED. Edimer's lead product candidate, EDI200, represents the first of a new class of molecules designed to permanently correct a developmental disorder in a pediatric population. Edimer was established in 2009 with investment from Third Rock Ventures and VI Partners.

For further information on Edimer Pharmaceuticals, please visit

www.edimerpharma.com.

CONTACTS:**Edimer Pharmaceuticals**

Jeff Behrens, 617-758-4300

Senior Director, Business Development and Operations

Paul Kidwell (Media)

Suda Communications LLC

617-296-3854